What Evolution Research Group Does

Evolution Research Group (ERG) is a mid-market contract research organization (CRO) founded in 2014, operating a network of clinical trial sites. Based in Edison, New Jersey, and employing 501-1000 staff, ERG specializes in the execution of clinical trials, focusing on patient recruitment, site management, and data collection for pharmaceutical and biotechnology sponsors. Their model integrates multiple research sites under one operational umbrella, aiming to streamline trial conduct and improve participant enrollment—a chronic bottleneck in drug development.

Why AI Matters at This Scale

For a growing CRO like ERG, operating at the 501-1000 employee scale, efficiency and scalability are critical to winning and delivering on sponsor contracts. The clinical trial industry is plagued with inefficiencies: nearly 80% of trials fail to enroll on time, and manual data processes are costly. AI presents a transformative lever. At this size, ERG has accumulated substantial operational data but likely lacks the vast IT resources of a global CRO. Targeted AI applications can thus provide a competitive edge, automating high-cost, repetitive tasks and enabling data-driven decision-making without the bureaucracy of larger enterprises. This allows ERG to offer sponsors faster, more predictable trial execution, directly impacting its revenue growth and market position.

Concrete AI Opportunities with ROI Framing

1. AI-Powered Patient Pre-Screening: Manually reviewing patient records against complex trial criteria is slow. An NLP system that ingests electronic health records (EHRs) to flag potential matches can cut pre-screening time by over 50%. For a mid-size CRO, this could translate to enrolling a 200-patient trial weeks faster, directly increasing site revenue and sponsor satisfaction. 2. Predictive Analytics for Site Selection: Choosing underperforming trial sites wastes monitoring resources and delays timelines. A machine learning model analyzing historical site performance (enrollment rates, data quality, protocol adherence) can predict the success likelihood of sites for new studies. Optimizing site selection could improve overall trial performance by 20-30%, enhancing resource utilization and reducing costly corrective actions. 3. Automated Clinical Data Quality Checks: Manual review of case report forms for errors is a significant labor cost. AI models trained to detect inconsistencies, missing data, or outlier values can triage issues for human review. Automating initial QC could reduce clinical data manager workload by an estimated 30%, freeing staff for higher-value analysis and reducing query cycles.

Deployment Risks Specific to This Size Band

ERG's mid-market scale presents unique AI adoption risks. Resource Constraints: Unlike large pharma, ERG cannot fund massive multi-year AI platform projects. Solutions must be modular, cloud-based, and have clear short-term ROI to justify investment. Integration Complexity: ERG likely uses several best-in-class SaaS platforms (e.g., EDC, CTMS). Integrating AI tools without disrupting these core systems requires careful API strategy and vendor cooperation, a challenge for a midsize IT team. Talent Gap: Attracting and retaining data scientists is difficult and expensive. Partnering with specialized AI vendors or leveraging managed ML platforms may be more viable than building in-house expertise. Regulatory Scrutiny: As a CRO, ERG's work is audited by sponsors and regulators. Any AI tool impacting trial data must be validated under FDA 21 CFR Part 11 and similar guidelines, requiring upfront investment in documentation and quality assurance processes that can strain limited compliance resources.